Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
TOP 2301: Neoadjuvant Chemo for NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Duke University
- Target Recruit Count
- 126
- Registration Number
- NCT06385262
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06384820
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Biohaven Therapeutics Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT06384807
- Locations
- 🇺🇸
NEXT Dallas, Dallas, Texas, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 560
- Registration Number
- NCT06246916
- Locations
- 🇺🇸
Eisenhower Medical Center, Rancho Mirage, California, United States
🇺🇸Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 136
- Registration Number
- NCT06219317
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪CHU Helora Pole Hospitalier Jolimont, Haine-Saint-Paul, Belgium
🇧🇪CHU Mont Godinne - UCL Namur, Yvoir, Belgium
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 22
- Registration Number
- NCT06205836
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 520
- Registration Number
- NCT06190951
- Locations
- 🇺🇸
California Pacific Medical Center Research Institute, San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Phase I Study of ANK-101 in Advanced Solid Tumors
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Ankyra Therapeutics, Inc
- Target Recruit Count
- 107
- Registration Number
- NCT06171750
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Servier Bio-Innovation LLC
- Target Recruit Count
- 176
- Registration Number
- NCT06162572
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸Hospital Universitario Virgen de La Victoria, Málaga, Spain
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇦🇺St Vincents Hospital, Fitzroy, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.